Global brokerage firm Jefferies has upgraded Zydus Lifesciences to a ‘Buy’ rating, citing the strength of the company’s US pipeline as a major growth driver. Jefferies raised its target price to Rs 1,450 from Rs 1,210, indicating a 30% upside from the previous closing price of Rs 1,113.80.
Mark Mobius, pioneer of emerging markets investing, dies at 89
Mark Mobius, a pioneer of emerging markets investing, has died at 89. Known for decades at Franklin Templeton Investments, he championed opportunities across developing economies,
April 15, 2026